E. David Crawford, MD, Editor-in-Chief

LEARNING CENTERS

Next Generation Androgen Deprivation Therapy

Editor: Celestia S. Higano, MD

Next Generation Genomics and Biomarkers

Editor: Leonard G. Gomella, MD

Next Generation Imaging

Editor: Gerald L. Andriole, MD

Next Generation nmCRPC

Editor: Jonathan Henderson, MD

Next Generation Nocturia

Editor: Kevin T. McVary, MD

LATEST CONTENT

Immunotherapy for Castrate-Resistant Prostate Cancer

Immunotherapy for Castrate-Resistant Prostate Cancer

Daniel P. Petrylak, MD, analyzes the current status of immunotherapy for prostate cancer, reviewing available options, emerging combination therapies, and immunotherapy clinical trials. He also emphasizes the impact of PD-L1 expression, microsatellite instability, and other mutations in prostate cancer on patient responses to immunotherapy. 

Bladder Cancer Journal Vol. 5 Issue 2

Bladder Cancer Journal Vol. 5 Issue 2

Bladder Cancer Journal Vol. 5 Issue 2Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer The fibroblast growth factor receptor 3 (FGFR3) plays critical roles in driving oncogenesis of a subset of patients with urothelial carcinomas (UC)....

Dr. Alicia Morgans: Putting Chemo Into Perspective

Dr. Alicia Morgans: Putting Chemo Into Perspective

This interview, "Dr. Alicia Morgans: Putting Chemo Into Perspective​," is provided by Grand Rounds in Urology's content partner, Prostatepedia. Dr. Alicia Morgans is a medical oncologist at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in...

Novel Oral Pharmacotherapies for ED: Are PDE5 Inhibitors the Final Answer?

Novel Oral Pharmacotherapies for ED: Are PDE5 Inhibitors the Final Answer?

Alan W. Shindel, MD, MAS, discusses the current treatment of erectile dysfunction (ED) with PDE5 inhibitors, as well as the limitations of the currently available drugs for ED patients. He also reviews a number of potential targets for novel ED treatments, including nitric oxide, soluble guanylate cyclase, the RhoA/Rho Kinase/ROCK pathway, and the Sonic Hedgehog protein.

Prevalence of Nocturia in US Women

Prevalence of Nocturia in US Women

Timothy K. Byler, MD, discusses the significant quality of life impact associated with nocturia, as well as underlying diseases and causative factors. He then reviews findings on the epidemiology of nocturia and its prevalence in women in the United States.

Latest Features

PT0 after NAC: Implications for Bladder Sparing and Prognosis

Androgen Receptor Targeted Treatments of Prostate Cancer Slide Deck

Pivotal Trial of MRI-Guided Transurethral Ultrasound Ablation in Men with Localized Prostate Cancer

Join the GRU Community

– Why Join? –